Seven oral triptans, which differ on a range of attributes important for treatment selection, are now available for treating migraine. US neurologists were surveyed to assess the relative importance of treatment attributes, prespecified by clinical relevance and availability of controlled study data, for selecting among oral triptans. Using a multiattribute decision model, we combined these data on the importance of treatment attributes with information on the relative performance of the oral triptans derived from a recent meta-analysis of controlled clinical trials.
|Original language||English (US)|
|Number of pages||8|
|Journal||Current pain and headache reports|
|State||Published - Dec 2004|
ASJC Scopus subject areas
- Clinical Neurology
- Anesthesiology and Pain Medicine